Repare Therapeutics develops precision oncology drugs using its proprietary SNIPRx® platform to identify and target genetic alterations in tumor cells. The company focuses on creating synthetic lethality-based therapies to address cancers with significant unmet medical needs.
Funding
$101.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers have specific genetic alterations that drive their growth, but developing drugs that selectively target these alterations is challenging. Traditional cancer treatments often lack precision, leading to off-target effects and limited efficacy in certain patient populations.
Solution
Repare Therapeutics utilizes its SNIPRx® platform to discover and develop precision oncology drugs that target specific genetic vulnerabilities in tumor cells. The company focuses on synthetic lethality, a strategy that exploits the dependence of cancer cells on certain genes for survival. By inhibiting these genes, Repare aims to selectively kill cancer cells while sparing healthy tissue, leading to more effective and less toxic treatments. The SNIPRx® platform enables the identification and validation of novel drug targets, as well as the development of targeted therapies designed to address cancers with significant unmet medical needs.
Target Audience
The primary target audience includes cancer patients with specific genetic alterations in their tumors, as well as oncologists and researchers seeking more effective and targeted cancer treatments.
Features
- SNIPRx® platform for identifying and validating synthetic lethal targets
- Development of targeted therapies that selectively kill cancer cells with specific genetic alterations
- Focus on cancers with significant unmet medical needs
- Pipeline of product candidates based on targets identified using the SNIPRx platform
- Clinical trials evaluating the safety and efficacy of Repare's drug candidates